People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Pharmaceuticals, Pharma, Other Health Care, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| E-scape Bio, Inc. | — | Biotechnology | Series C | $167.1M | $2.8B | 2015 |
| Silverback Therapeutics, Inc. | — | Biotechnology | Series C | $139.3M | $3.2B | 2020 |
| Edgewise Therapeutics, Inc. | — | Biotechnology | Series C | $120.1M | $3.3B | 2019 |
| Adaptimmune Ltd | — | Biotechnology | Series D+ | $103.8M | $4.3B | 2014 |
| ProNAi Therapeutics Inc | — | Biotechnology | Series C | $77.7M | $2.4B | 2014 |
| Principia Biopharma Inc. | — | Biotechnology | Series C | $77.4M | $2.0B | 2015 |
| PMV Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $73.7M | $2.6B | 2017 |
| Sparrow Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $73.3M | $386.2M | 2020 |
| Prevail Therapeutics Inc. | — | Pharma | Series C | $57.0M | $2.0B | 2018 |
| CranioVation, Inc. | — | Other Health Care | Series B | $56.7M | $174.9M | 2020 |
| Ocunexus Therapeutics, Inc. | — | Biotechnology | Series B | $53.2M | $292.3M | 2011 |
| Gennao Bio, Inc. | — | Biotechnology | Series B | $47.5M | $211.6M | 2022 |
| Cleave Biosciences, Inc. | — | Biotechnology | Series B | $37.9M | $475.1M | 2016 |
| Synthorx, Inc. | — | Biotechnology | Series B | $34.7M | $1.1B | 2018 |
| Trubion Pharmaceuticals, Inc | — | Biotechnology | Series A | $10.0M | $361.5M | 2009 |
| EQDerivatives, Inc. | — | Other | Pre-Seed | $750K | $17.3M | 2019 |
Peter Thompson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Thompson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan Root | 4 | 16 |
| Laura Shawver | 3 | 6 |
| Klaus Veitinger | 2 | 6 |
| Carl Gordon | 1 | 24 |
| Steven Gillis | 1 | 23 |
| Asish Xavier | 1 | 18 |
| ANDREW LEVIN | 1 | 17 |
| Ali Behbahani | 1 | 17 |
| Andrew Schwab | 1 | 16 |
| LEON CHEN | 1 | 15 |
| James Topper | 1 | 12 |
| Patrick Heron | 1 | 11 |
| Arnold Oronsky | 1 | 10 |
| Srinivas Akkaraju | 1 | 10 |
| Chau Khuong | 1 | 9 |
| David Mott | 1 | 9 |
| Albert Cha | 1 | 9 |
| Stephen Squinto | 1 | 8 |
| Brian Levy | 1 | 8 |
| James Blair | 1 | 8 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.